User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Residual macrovascular risk in 2013: what have we learned?

Primary tabs

download
  • Open access
  • PDF
  • 792.43 K
Fruchart, Jean-Charles Davignon, Jean Hermans, Michel [UCL] Al-Rubeaan, Khalid Amarenco, Pierre Residual Risk Reduction Initiative (R3i)

Cardiovascular disease poses a major challenge for the 21st century, exacerbated by the pandemics of obesity, metabolic syndrome and type 2 diabetes. While best standards of care, including high-dose statins, can ameliorate the risk of vascular complications, patients remain at high risk of cardiovascular events. The Residual Risk Reduction Initiative (R3i) has previously highlighted atherogenic dyslipidaemia, defined as the imbalance between proatherogenic triglyceride-rich apolipoprotein B-containing-lipoproteins and antiatherogenic apolipoprotein A-I-lipoproteins (as in high-density lipoprotein, HDL), as an important modifiable contributor to lipid-related residual cardiovascular risk, especially in insulin-resistant conditions. As part of its mission to improve awareness and clinical management of atherogenic dyslipidaemia, the R3i has identified three key priorities for action: i) to improve recognition of atherogenic dyslipidaemia in patients at high cardiometabolic risk with or without diabetes; ii) to improve implementation and adherence to guideline-based therapies; and iii) to improve therapeutic strategies for managing atherogenic dyslipidaemia. The R3i believes that monitoring of non-HDL cholesterol provides a simple, practical tool for treatment decisions regarding the management of lipid-related residual cardiovascular risk. Addition of a fibrate, niacin (North and South America), omega-3 fatty acids or ezetimibe are all options for combination with a statin to further reduce non-HDL cholesterol, although lacking in hard evidence for cardiovascular outcome benefits. Several emerging treatments may offer promise. These include the next generation peroxisome proliferator-activated receptorα agonists, cholesteryl ester transfer protein inhibitors and monoclonal antibody therapy targeting proprotein convertase subtilisin/kexin type 9. However, long-term outcomes and safety data are clearly needed. In conclusion, the R3i believes that ongoing trials with these novel treatments may help to define the optimal management of atherogenic dyslipidaemia to reduce the clinical and socioeconomic burden of residual cardiovascular risk.

Document type Article de périodique (Journal article) – Synthèse de littérature
Access type Accès libre
Publication date 2014
Language Anglais
Journal information "Cardiovascular Diabetology" - Vol. 13, no.1, p. 26 (2014)
Peer reviewed yes
Publisher BioMed Central Ltd. ((United Kingdom) London)
e-issn 1475-2840
Publication status Publié
Affiliations UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition
UCL - (SLuc) Service d'endocrinologie et de nutrition
MESH Subject Animals ; Cardiovascular Diseases ; Diabetes Mellitus, Type 2 ; Dyslipidemias ; Humans ; Learning ; Risk Factors
Links
  1. Lozano Rafael, Naghavi Mohsen, Foreman Kyle, Lim Stephen, Shibuya Kenji, Aboyans Victor, Abraham Jerry, Adair Timothy, Aggarwal Rakesh, Ahn Stephanie Y, AlMazroa Mohammad A, Alvarado Miriam, Anderson H Ross, Anderson Laurie M, Andrews Kathryn G, Atkinson Charles, Baddour Larry M, Barker-Collo Suzanne, Bartels David H, Bell Michelle L, Benjamin Emelia J, Bennett Derrick, Bhalla Kavi, Bikbov Boris, Abdulhak Aref Bin, Birbeck Gretchen, Blyth Fiona, Bolliger Ian, Boufous Soufiane, Bucello Chiara, Burch Michael, Burney Peter, Carapetis Jonathan, Chen Honglei, Chou David, Chugh Sumeet S, Coffeng Luc E, Colan Steven D, Colquhoun Samantha, Colson K Ellicott, Condon John, Connor Myles D, Cooper Leslie T, Corriere Matthew, Cortinovis Monica, de Vaccaro Karen Courville, Couser William, Cowie Benjamin C, Criqui Michael H, Cross Marita, Dabhadkar Kaustubh C, Dahodwala Nabila, De Leo Diego, Degenhardt Louisa, Delossantos Allyne, Denenberg Julie, Des Jarlais Don C, Dharmaratne Samath D, Dorsey E Ray, Driscoll Tim, Duber Herbert, Ebel Beth, Erwin Patricia J, Espindola Patricia, Ezzati Majid, Feigin Valery, Flaxman Abraham D, Forouzanfar Mohammad H, Fowkes Francis Gerry R, Franklin Richard, Fransen Marlene, Freeman Michael K, Gabriel Sherine E, Gakidou Emmanuela, Gaspari Flavio, Gillum Richard F, Gonzalez-Medina Diego, Halasa Yara A, Haring Diana, Harrison James E, Havmoeller Rasmus, Hay Roderick J, Hoen Bruno, Hotez Peter J, Hoy Damian, Jacobsen Kathryn H, James Spencer L, Jasrasaria Rashmi, Jayaraman Sudha, Johns Nicole, Karthikeyan Ganesan, Kassebaum Nicholas, Keren Andre, Khoo Jon-Paul, Knowlton Lisa Marie, Kobusingye Olive, Koranteng Adofo, Krishnamurthi Rita, Lipnick Michael, Lipshultz Steven E, Ohno Summer Lockett, Mabweijano Jacqueline, MacIntyre Michael F, Mallinger Leslie, March Lyn, Marks Guy B, Marks Robin, Matsumori Akira, Matzopoulos Richard, Mayosi Bongani M, McAnulty John H, McDermott Mary M, McGrath John, Memish Ziad A, Mensah George A, Merriman Tony R, Michaud Catherine, Miller Matthew, Miller Ted R, Mock Charles, Mocumbi Ana Olga, Mokdad Ali A, Moran Andrew, Mulholland Kim, Nair M Nathan, Naldi Luigi, Narayan K M Venkat, Nasseri Kiumarss, Norman Paul, O'Donnell Martin, Omer Saad B, Ortblad Katrina, Osborne Richard, Ozgediz Doruk, Pahari Bishnu, Pandian Jeyaraj Durai, Rivero Andrea Panozo, Padilla Rogelio Perez, Perez-Ruiz Fernando, Perico Norberto, Phillips David, Pierce Kelsey, Pope C Arden, Porrini Esteban, Pourmalek Farshad, Raju Murugesan, Ranganathan Dharani, Rehm Jürgen T, Rein David B, Remuzzi Guiseppe, Rivara Frederick P, Roberts Thomas, De León Felipe Rodriguez, Rosenfeld Lisa C, Rushton Lesley, Sacco Ralph L, Salomon Joshua A, Sampson Uchechukwu, Sanman Ella, Schwebel David C, Segui-Gomez Maria, Shepard Donald S, Singh David, Singleton Jessica, Sliwa Karen, Smith Emma, Steer Andrew, Taylor Jennifer A, Thomas Bernadette, Tleyjeh Imad M, Towbin Jeffrey A, Truelsen Thomas, Undurraga Eduardo A, Venketasubramanian N, Vijayakumar Lakshmi, Vos Theo, Wagner Gregory R, Wang Mengru, Wang Wenzhi, Watt Kerrianne, Weinstock Martin A, Weintraub Robert, Wilkinson James D, Woolf Anthony D, Wulf Sarah, Yeh Pon-Hsiu, Yip Paul, Zabetian Azadeh, Zheng Zhi-Jie, Lopez Alan D, Murray Christopher JL, Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, 10.1016/s0140-6736(12)61728-0
  2. Yusuf Salim, Hawken Steven, Ôunpuu Stephanie, Dans Tony, Avezum Alvaro, Lanas Fernando, McQueen Matthew, Budaj Andrzej, Pais Prem, Varigos John, Lisheng Liu, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, 10.1016/s0140-6736(04)17018-9
  3. Lanas F., Avezum A., Bautista L. E., Diaz R., Luna M., Islam S., Yusuf S., , Risk Factors for Acute Myocardial Infarction in Latin America: The INTERHEART Latin American Study, 10.1161/circulationaha.106.633552
  4. Fruchart Jean-Charles, Sacks Frank M, Hermans Michel P, Assmann Gerd, Brown W Virgil, Ceska Richard, Chapman M John, Dodson Paul M, Fioretto Paola, Ginsberg Henry N, Kadowaki Takashi, Lablanche Jean-Marc, Marx Nikolaus, Plutzky Jorge, Reiner Zeljko, Rosenson Robert S, Staels Bart, Stock Jane K, Sy Rody, Wanner Christoph, Zambon Alberto, Zimmet Paul, The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients, 10.3132/dvdr.2008.046
  5. Chapman M. John, Ginsberg Henry N., Amarenco Pierre, Andreotti Felicita, Borén Jan, Catapano Alberico L., Descamps Olivier S., Fisher Edward, Kovanen Petri T., Kuivenhoven Jan Albert, Lesnik Philippe, Masana Luis, Nordestgaard Børge G., Ray Kausik K., Reiner Zeljko, Taskinen Marja-Riitta, Tokgözoglu Lale, Tybjærg-Hansen Anne, Watts Gerald F., Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management, 10.1093/eurheartj/ehr112
  6. Reiner Ž., Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update, 10.1016/j.numecd.2013.05.002
  7. The Emerging Risk Factors Collaboration*, Major Lipids, Apolipoproteins, and Risk of Vascular Disease, 10.1001/jama.2009.1619
  8. Assmann G., Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Munster (PROCAM) Study, 10.1161/hc0302.102575
  9. Besler Christian, Heinrich Kathrin, Riwanto Meliana, F. Luscher Thomas, Landmesser Ulf, High-Density Lipoprotein-Mediated Anti-Atherosclerotic and Endothelial-Protective Effects: A Potential Novel Therapeutic Target in Cardiovascular Disease, 10.2174/138161210791051013
  10. Assmann G., Schulte H., Cullen P., Seedorf U., Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study, 10.1111/j.1365-2362.2007.01888.x
  11. Voight Benjamin F, Peloso Gina M, Orho-Melander Marju, Frikke-Schmidt Ruth, Barbalic Maja, Jensen Majken K, Hindy George, Hólm Hilma, Ding Eric L, Johnson Toby, Schunkert Heribert, Samani Nilesh J, Clarke Robert, Hopewell Jemma C, Thompson John F, Li Mingyao, Thorleifsson Gudmar, Newton-Cheh Christopher, Musunuru Kiran, Pirruccello James P, Saleheen Danish, Chen Li, Stewart Alexandre FR, Schillert Arne, Thorsteinsdottir Unnur, Thorgeirsson Gudmundur, Anand Sonia, Engert James C, Morgan Thomas, Spertus John, Stoll Monika, Berger Klaus, Martinelli Nicola, Girelli Domenico, McKeown Pascal P, Patterson Christopher C, Epstein Stephen E, Devaney Joseph, Burnett Mary-Susan, Mooser Vincent, Ripatti Samuli, Surakka Ida, Nieminen Markku S, Sinisalo Juha, Lokki Marja-Liisa, Perola Markus, Havulinna Aki, de Faire Ulf, Gigante Bruna, Ingelsson Erik, Zeller Tanja, Wild Philipp, de Bakker Paul I W, Klungel Olaf H, Maitland-van der Zee Anke-Hilse, Peters Bas J M, de Boer Anthonius, Grobbee Diederick E, Kamphuisen Pieter W, Deneer Vera H M, Elbers Clara C, Onland-Moret N Charlotte, Hofker Marten H, Wijmenga Cisca, Verschuren WM Monique, Boer Jolanda MA, van der Schouw Yvonne T, Rasheed Asif, Frossard Philippe, Demissie Serkalem, Willer Cristen, Do Ron, Ordovas Jose M, Abecasis Gonçalo R, Boehnke Michael, Mohlke Karen L, Daly Mark J, Guiducci Candace, Burtt Noël P, Surti Aarti, Gonzalez Elena, Purcell Shaun, Gabriel Stacey, Marrugat Jaume, Peden John, Erdmann Jeanette, Diemert Patrick, Willenborg Christina, König Inke R, Fischer Marcus, Hengstenberg Christian, Ziegler Andreas, Buysschaert Ian, Lambrechts Diether, Van de Werf Frans, Fox Keith A, El Mokhtari Nour Eddine, Rubin Diana, Schrezenmeir Jürgen, Schreiber Stefan, Schäfer Arne, Danesh John, Blankenberg Stefan, Roberts Robert, McPherson Ruth, Watkins Hugh, Hall Alistair S, Overvad Kim, Rimm Eric, Boerwinkle Eric, Tybjaerg-Hansen Anne, Cupples L Adrienne, Reilly Muredach P, Melander Olle, Mannucci Pier M, Ardissino Diego, Siscovick David, Elosua Roberto, Stefansson Kari, O'Donnell Christopher J, Salomaa Veikko, Rader Daniel J, Peltonen Leena, Schwartz Stephen M, Altshuler David, Kathiresan Sekar, Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study, 10.1016/s0140-6736(12)60312-2
  12. Rosenson R. S., Brewer H. B., Davidson W. S., Fayad Z. A., Fuster V., Goldstein J., Hellerstein M., Jiang X.-C., Phillips M. C., Rader D. J., Remaley A. T., Rothblat G. H., Tall A. R., Yvan-Charvet L., Cholesterol Efflux and Atheroprotection: Advancing the Concept of Reverse Cholesterol Transport, 10.1161/circulationaha.111.066589
  13. Otvos J. D., Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial, 10.1161/circulationaha.105.565135
  14. Asztalos Bela F., Collins Dorothea, Horvath Katalin V., Bloomfield Hanna E., Robins Sander J., Schaefer Ernst J., Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial, 10.1016/j.metabol.2007.08.009
  15. Kontush A., Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis, 10.1124/pr.58.3.1
  16. Alwaili Khalid, Bailey Dana, Awan Zuhier, Bailey Swneke D., Ruel Isabelle, Hafiane Anouar, Krimbou Larbi, Laboissiere Sylvie, Genest Jacques, The HDL proteome in acute coronary syndromes shifts to an inflammatory profile, 10.1016/j.bbalip.2011.07.013
  17. Besler Christian, Lüscher Thomas F., Landmesser Ulf, Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease : HDL in cardiovascular disease, 10.1002/emmm.201200224
  18. Angeloni E., Paneni F., Landmesser U., Benedetto U., Melina G., Luscher T. F., Volpe M., Sinatra R., Cosentino F., Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting, 10.1093/eurheartj/eht163
  19. Sarwar N., Danesh J., Eiriksdottir G., Sigurdsson G., Wareham N., Bingham S., Boekholdt S. M., Khaw K.-T., Gudnason V., Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies, 10.1161/circulationaha.106.637793
  20. Nordestgaard Børge G., Benn Marianne, Schnohr Peter, Tybjærg-Hansen Anne, Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women, 10.1001/jama.298.3.299
  21. Miller M., Stone N. J., Ballantyne C., Bittner V., Criqui M. H., Ginsberg H. N., Goldberg A. C., Howard W. J., Jacobson M. S., Kris-Etherton P. M., Lennie T. A., Levi M., Mazzone T., Pennathur S., , Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association, 10.1161/cir.0b013e3182160726
  22. Ginsberg H. N., New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism, 10.1161/01.cir.0000035280.64322.31
  23. Patel Sanjay, Puranik Rajesh, Nakhla Shirley, Lundman Pia, Stocker Roland, Wang Xiao S., Lambert Gilles, Rye Kerry-Ann, Barter Philip J., Nicholls Stephen J., Celermajer David S., Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins, 10.1016/j.atherosclerosis.2008.07.047
  24. Palmer Anna M, Murphy Nuala, Graham Annette, Triglyceride-rich lipoproteins inhibit cholesterol efflux to apolipoprotein (apo) A1 from human macrophage foam cells, 10.1016/j.atherosclerosis.2003.12.001
  25. Twickler T.B., Elevated Remnant-Like Particle Cholesterol Concentration: A Characteristic Feature of the Atherogenic Lipoprotein Phenotype, 10.1161/01.cir.0000125278.58527.f3
  26. Varbo Anette, Benn Marianne, Tybjærg-Hansen Anne, Jørgensen Anders B., Frikke-Schmidt Ruth, Nordestgaard Børge G., Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease, 10.1016/j.jacc.2012.08.1026
  27. Fukushima Hironobu, Sugiyama Seigo, Honda Osamu, Koide Shunichi, Nakamura Shinichi, Sakamoto Tomohiro, Yoshimura Michihiro, Ogawa Hisao, Fujioka Daisuke, Kugiyama Kiyotaka, Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type ii diabetes mellitus, 10.1016/j.jacc.2003.09.074
  28. Nakamura Takamitsu, Takano Hajime, Umetani Ken, Kawabata Ken-ichi, Obata Jyun-ei, Kitta Yoshinobu, Kodama Yasushi, Mende Akira, Ichigi Yoshihide, Fujioka Daisuke, Saito Yukio, Kugiyama Kiyotaka, Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome, 10.1016/j.atherosclerosis.2005.01.012
  29. Carey Vincent J., Bishop Louise, Laranjo Nancy, Harshfield Benjamin J., Kwiat Carolyn, Sacks Frank M., Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control, 10.1016/j.amjcard.2010.05.002
  30. Assmann Gerd, Cullen Paul, Schulte Helmut, Non-LDL-related dyslipidaemia and coronary risk: a case-control study, 10.1177/1479164110372640
  31. Hermans Michel P, Ahn Sylvie A, Rousseau Michel F, The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females, 10.1186/1476-511x-11-132
  32. Hermans Michel P, Ahn Sylvie A, Rousseau Michel F, log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males, 10.1186/1475-2840-9-88
  33. Onat Altan, Can Günay, Kaya Hasan, Hergenç Gülay, “Atherogenic index of plasma” (log10 triglyceride/high-density lipoprotein−cholesterol) predicts high blood pressure, diabetes, and vascular events, 10.1016/j.jacl.2010.02.005
  34. Tenenbaum Alexander, Fisman Enrique Z, Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction, 10.1186/1475-2840-11-125
  35. Scott R., O'Brien R., Fulcher G., Pardy C., d'Emden M., Tse D., Taskinen M.-R., Ehnholm C., Keech A., , Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, 10.2337/dc08-1543
  36. Jun Min, Foote Celine, Lv Jicheng, Neal Bruce, Patel Anushka, Nicholls Stephen J, Grobbee Diederick E, Cass Alan, Chalmers John, Perkovic Vlado, Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis, 10.1016/s0140-6736(10)60656-3
  37. Ziouzenkova Ouliana, Plutzky Jorge, Lipolytic PPAR activation: new insights into the intersection of triglycerides and inflammation? : , 10.1097/01.mco.0000134358.46159.61
  38. Rip J., Lipoprotein Lipase S447X: A Naturally Occurring Gain-of-Function Mutation, 10.1161/01.atv.0000219283.10832.43
  39. Reyes-Soffer G., Ngai C. I., Lovato L., Karmally W., Ramakrishnan R., Holleran S., Ginsberg H. N., Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial, 10.2337/dc11-2556
  40. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TME, Moffitt MS, Taskinen M-R, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG, Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial, 10.1016/s0140-6736(07)61607-9
  41. Rajamani Kushwin, Colman Peter G, Li Li Ping, Best James D, Voysey Merryn, D'Emden Michael C, Laakso Markku, Baker John R, Keech Anthony C, Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial, 10.1016/s0140-6736(09)60698-x
  42. Bonds D. E., Craven T. E., Buse J., Crouse J. R., Cuddihy R., Elam M., Ginsberg H. N., Kirchner K., Marcovina S., Mychaleckyj J. C., O’Connor P. J., Sperl-Hillen J.-A., Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience, 10.1007/s00125-012-2524-2
  43. Mychaleckyj J. C., Craven T., Nayak U., Buse J., Crouse J. R., Elam M., Kirchner K., Lorber D., Marcovina S., Sivitz W., Sperl-Hillen J., Bonds D. E., Ginsberg H. N., Reversibility of Fenofibrate Therapy-Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants, 10.2337/dc11-1811
  44. Davis T. M. E., , Ting R., Best J. D., Donoghoe M. W., Drury P. L., Sullivan D. R., Jenkins A. J., O’Connell R. L., Whiting M. J., Glasziou P. P., Simes R. J., Kesäniemi Y. A., Gebski V. J., Scott R. S., Keech A. C., Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study, 10.1007/s00125-010-1951-1
  45. Ting R.-D., Keech A. C., Drury P. L., Donoghoe M. W., Hedley J., Jenkins A. J., Davis T. M. E., Lehto S., Celermajer D., Simes R. J., Rajamani K., Stanton K., , Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment: The FIELD Study, 10.2337/dc11-1109
  46. Guyton John R., Slee April E., Anderson Todd, Fleg Jerome L., Goldberg Ronald B., Kashyap Moti L., Marcovina Santica M., Nash Stephen D., O'Brien Kevin D., Weintraub William S., Xu Ping, Zhao Xue-Qiao, Boden William E., Relationship of Lipoproteins to Cardiovascular Events, 10.1016/j.jacc.2013.07.023
  47. Yokoyama Mitsuhiro, Origasa Hideki, Matsuzaki Masunori, Matsuzawa Yuji, Saito Yasushi, Ishikawa Yuichi, Oikawa Shinichi, Sasaki Jun, Hishida Hitoshi, Itakura Hiroshige, Kita Toru, Kitabatake Akira, Nakaya Noriaki, Sakata Toshiie, Shimada Kazuyuki, Shirato Kunio, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis, 10.1016/s0140-6736(07)60527-3
  48. Saito Yasushi, Yokoyama Mitsuhiro, Origasa Hideki, Matsuzaki Masunori, Matsuzawa Yuji, Ishikawa Yuichi, Oikawa Shinichi, Sasaki Jun, Hishida Hitoshi, Itakura Hiroshige, Kita Toru, Kitabatake Akira, Nakaya Noriaki, Sakata Toshiie, Shimada Kazuyuki, Shirato Kunio, Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS), 10.1016/j.atherosclerosis.2008.06.003
  49. Kromhout Daan, Giltay Erik J., Geleijnse Johanna M., n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction, 10.1056/nejmoa1003603
  50. Rizos Evangelos C., Ntzani Evangelia E., Bika Eftychia, Kostapanos Michael S., Elisaf Moses S., Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events : A Systematic Review and Meta-analysis, 10.1001/2012.jama.11374
  51. Brasky Theodore M., Darke Amy K., Song Xiaoling, Tangen Catherine M., Goodman Phyllis J., Thompson Ian M., Meyskens Frank L., Goodman Gary E., Minasian Lori M., Parnes Howard L., Klein Eric A., Kristal Alan R., Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial, 10.1093/jnci/djt174
  52. Brasky T. M., Till C., White E., Neuhouser M. L., Song X., Goodman P., Thompson I. M., King I. B., Albanes D., Kristal A. R., Serum Phospholipid Fatty Acids and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial, 10.1093/aje/kwr027
  53. Morrone Doralisa, Weintraub William S., Toth Peter P., Hanson Mary E., Lowe Robert S., Lin Jianxin, Shah Arvind K., Tershakovec Andrew M., Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials, 10.1016/j.atherosclerosis.2012.02.016
  54. Baigent Colin, Landray Martin J, Reith Christina, Emberson Jonathan, Wheeler David C, Tomson Charles, Wanner Christoph, Krane Vera, Cass Alan, Craig Jonathan, Neal Bruce, Jiang Lixin, Hooi Lai Seong, Levin Adeera, Agodoa Lawrence, Gaziano Mike, Kasiske Bertram, Walker Robert, Massy Ziad A, Feldt-Rasmussen Bo, Krairittichai Udom, Ophascharoensuk Vuddidhej, Fellström Bengt, Holdaas Hallvard, Tesar Vladimir, Wiecek Andrzej, Grobbee Diederick, de Zeeuw Dick, Grönhagen-Riska Carola, Dasgupta Tanaji, Lewis David, Herrington William, Mafham Marion, Majoni William, Wallendszus Karl, Grimm Richard, Pedersen Terje, Tobert Jonathan, Armitage Jane, Baxter Alex, Bray Christopher, Chen Yiping, Chen Zhengming, Hill Michael, Knott Carol, Parish Sarah, Simpson David, Sleight Peter, Young Alan, Collins Rory, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial, 10.1016/s0140-6736(11)60739-3
  55. Rossebø Anne B., Pedersen Terje R., Boman Kurt, Brudi Philippe, Chambers John B., Egstrup Kenneth, Gerdts Eva, Gohlke-Bärwolf Christa, Holme Ingar, Kesäniemi Y. Antero, Malbecq William, Nienaber Christoph A., Ray Simon, Skjærpe Terje, Wachtell Kristian, Willenheimer Ronnie, Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis, 10.1056/nejmoa0804602
  56. Kastelein John J.P., Akdim Fatima, Stroes Erik S.G., Zwinderman Aeilko H., Bots Michiel L., Stalenhoef Anton F.H., Visseren Frank L.J., Sijbrands Eric J.G., Trip Mieke D., Stein Evan A., Gaudet Daniel, Duivenvoorden Raphael, Veltri Enrico P., Marais A. David, de Groot Eric, Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia, 10.1056/nejmoa0800742
  57. Buchwald Henry, Varco Richard L., Matts John P., Long John M., Fitch Laurie L., Campbell Gilbert S., Pearce Malcolm B., Yellin Albert E., Edmiston W. Allan, Smink Robert D., Sawin Henry S., Campos Christian T., Hansen Betty J., Tuna Naip, Karnegis James N., Sanmarco Miguel E., Amplatz Kurt, Castaneda-Zuniga Wilfredo R., Hunter David W., Bissett Joseph K., Weber Frederic J., Stevenson James W., Leon Arthur S., Chalmers Thomas C., Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with Hypercholesterolemia : Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH), 10.1056/nejm199010043231404
  58. Pyorala K., Pedersen T. R., Kjekshus J., Faergeman O., Olsson A. G., Thorgeirsson G., , Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S), 10.2337/diacare.20.4.614
  59. Nakamura Tsukasa, Sato Eiichi, Fujiwara Nobuharu, Kawagoe Yasuhiro, Ueda Yoshihiko, Suzuki Tsukasa, Ueda Seiji, Fukami Kei, Okuda Seiya, Yamagishi Sho-ichi, Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner, 10.1016/j.phrs.2009.07.011
  60. Cannon Christopher P., Giugliano Robert P., Blazing Michael A., Harrington Robert A., Peterson John L., Sisk Christine McCrary, Strony John, Musliner Thomas A., McCabe Carolyn H., Veltri Enrico, Braunwald Eugene, Califf Robert M., Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes, 10.1016/j.ahj.2008.07.023
  61. Henry Robert R, Lincoff A Michael, Mudaliar Sunder, Rabbia Michael, Chognot Cathy, Herz Matthias, Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study, 10.1016/s0140-6736(09)60870-9
  62. Younk Lisa M, Uhl Lisa, Davis Stephen N, Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk, 10.1517/17425255.2011.579561
  63. Cariou B., Zair Y., Staels B., Bruckert E., Effects of the New Dual PPAR /  Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism, 10.2337/dc11-0093
  64. Cannon Christopher P., Shah Sukrut, Dansky Hayes M., Davidson Michael, Brinton Eliot A., Gotto Antonio M., Stepanavage Michael, Liu Sherry Xueyu, Gibbons Patrice, Ashraf Tanya B., Zafarino Jennifer, Mitchel Yale, Barter Philip, Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease, 10.1056/nejmoa1009744
  65. McKenney James M., Koren Michael J., Kereiakes Dean J., Hanotin Corinne, Ferrand Anne-Catherine, Stein Evan A., Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy, 10.1016/j.jacc.2012.03.007
  66. Giugliano Robert P, Desai Nihar R, Kohli Payal, Rogers William J, Somaratne Ransi, Huang Fannie, Liu Thomas, Mohanavelu Satishkumar, Hoffman Elaine B, McDonald Shannon T, Abrahamsen Timothy E, Wasserman Scott M, Scott Robert, Sabatine Marc S, Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study, 10.1016/s0140-6736(12)61770-x
  67. Fruchart Jean-Charles, Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists, 10.1186/1475-2840-12-82
  68. Cariou B., Hanf R., Lambert-Porcheron S., Zair Y., Sauvinet V., Noel B., Flet L., Vidal H., Staels B., Laville M., Dual Peroxisome Proliferator-Activated Receptor  /  Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects, 10.2337/dc12-2012
  69. HARANO Yutaka, MIYAWAKI Takeshi, NABIKI Junko, SHIBACHI Miki, ADACHI Tomomi, IKEDA Michiko, UEDA Fukuhiro, NAKANO Takamitsu, Development of Cookie Test for the Simultaneous Determination of Glucose Intolerance, Hyperinsulinemia, Insulin Resistance and Postprandial Dyslipidemia, 10.1507/endocrj.53.173
  70. Barter Philip J., Caulfield Mark, Eriksson Mats, Grundy Scott M., Kastelein John J.P., Komajda Michel, Lopez-Sendon Jose, Mosca Lori, Tardif Jean-Claude, Waters David D., Shear Charles L., Revkin James H., Buhr Kevin A., Fisher Marian R., Tall Alan R., Brewer Bryan, Effects of Torcetrapib in Patients at High Risk for Coronary Events, 10.1056/nejmoa0706628
  71. Forrest M J, Bloomfield D, Briscoe R J, Brown P N, Cumiskey A-M, Ehrhart J, Hershey J C, Keller W J, Ma X, McPherson H E, Messina E, Peterson L B, Sharif-Rodriguez W, Siegl P K S, Sinclair P J, Sparrow C P, Stevenson A S, Sun S-Y, Tsai C, Vargas H, Walker M, West S H, White V, Woltmann R F, Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone, 10.1038/bjp.2008.229
  72. Schwartz Gregory G., Olsson Anders G., Abt Markus, Ballantyne Christie M., Barter Philip J., Brumm Jochen, Chaitman Bernard R., Holme Ingar M., Kallend David, Leiter Lawrence A., Leitersdorf Eran, McMurray John J.V., Mundl Hardi, Nicholls Stephen J., Shah Prediman K., Tardif Jean-Claude, Wright R. Scott, Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome, 10.1056/nejmoa1206797
  73. Lambert Gilles, Sjouke Barbara, Choque Benjamin, Kastelein John J. P., Hovingh G. Kees, The PCSK9 decade : Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases, 10.1194/jlr.r026658
  74. Nissen Steven E., Tsunoda Taro, Tuzcu E. Murat, Schoenhagen Paul, Cooper Christopher J., Yasin Muhammad, Eaton Gregory M., Lauer Michael A., Sheldon W. Scott, Grines Cindy L., Halpern Stephen, Crowe Tim, Blankenship James C., Kerensky Richard, Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes : A Randomized Controlled Trial, 10.1001/jama.290.17.2292
  75. Diditchenko S., Gille A., Pragst I., Stadler D., Waelchli M., Hamilton R., Leis A., Wright S. D., Novel Formulation of a Reconstituted High-Density Lipoprotein (CSL112) Dramatically Enhances ABCA1-Dependent Cholesterol Efflux, 10.1161/atvbaha.113.301981
Bibliographic reference Fruchart, Jean-Charles ; Davignon, Jean ; Hermans, Michel ; Al-Rubeaan, Khalid ; Amarenco, Pierre ; et. al. Residual macrovascular risk in 2013: what have we learned?. In: Cardiovascular Diabetology, Vol. 13, no.1, p. 26 (2014)
Permanent URL http://hdl.handle.net/2078.1/161283